PDT Partners LLC Purchases 4,821 Shares of Humana Inc. (NYSE:HUM)

PDT Partners LLC raised its position in shares of Humana Inc. (NYSE:HUM) by 118.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,881 shares of the insurance provider’s stock after acquiring an additional 4,821 shares during the period. PDT Partners LLC’s holdings in Humana were worth $2,253,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the stock. Dodge & Cox lifted its position in shares of Humana by 106.7% in the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock worth $2,587,345,000 after acquiring an additional 5,264,045 shares during the period. Vanguard Group Inc. raised its stake in shares of Humana by 15.8% in the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock valued at $3,254,899,000 after purchasing an additional 1,751,857 shares in the last quarter. Norges Bank bought a new position in Humana in the fourth quarter worth $416,202,000. Pzena Investment Management LLC boosted its stake in Humana by 44.0% during the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after buying an additional 1,103,132 shares in the last quarter. Finally, Boston Partners increased its holdings in Humana by 435.8% in the 4th quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock valued at $279,236,000 after buying an additional 893,637 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

HUM opened at $258.91 on Wednesday. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The company’s 50 day simple moving average is $266.05 and its 200-day simple moving average is $270.76. The stock has a market capitalization of $31.25 billion, a P/E ratio of 26.02, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Sell-side analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.37%. Humana’s dividend payout ratio is currently 35.58%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on HUM. Mizuho lifted their target price on shares of Humana from $305.00 to $316.00 and gave the company an “outperform” rating in a research report on Wednesday, April 9th. Guggenheim started coverage on shares of Humana in a research note on Wednesday, April 9th. They issued a “buy” rating and a $326.00 target price on the stock. Piper Sandler upped their target price on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. JPMorgan Chase & Co. lowered their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Finally, Robert W. Baird upped their target price on shares of Humana from $270.00 to $300.00 and gave the company a “neutral” rating in a research note on Tuesday, April 15th. Seventeen equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Humana currently has an average rating of “Hold” and an average target price of $284.90.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.